EP1173254A2 - Nouveau traitement de conditions neurotraumatiques avec un inhibiteur de raf - Google Patents

Nouveau traitement de conditions neurotraumatiques avec un inhibiteur de raf

Info

Publication number
EP1173254A2
EP1173254A2 EP00927054A EP00927054A EP1173254A2 EP 1173254 A2 EP1173254 A2 EP 1173254A2 EP 00927054 A EP00927054 A EP 00927054A EP 00927054 A EP00927054 A EP 00927054A EP 1173254 A2 EP1173254 A2 EP 1173254A2
Authority
EP
European Patent Office
Prior art keywords
raf
raf inhibitor
inhibitors
neurotraumatic
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00927054A
Other languages
German (de)
English (en)
Inventor
Elaine Alison Irving
Andrew A. Parsons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9909650.5A external-priority patent/GB9909650D0/en
Priority claimed from GBGB9916655.5A external-priority patent/GB9916655D0/en
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of EP1173254A2 publication Critical patent/EP1173254A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • Raf protein kinases are key components of signal transduction pathways by which specific extracellular stimuli elicit precise cellular responses in mammalian cells.
  • Activated cell surface receptors activate ras/rap proteins at the inner aspect of the plasmamembrane which in turn recruit and activate Raf proteins.
  • Activated Raf proteins phosphorylate and activate the intracellular protein kinases MEK1 and MEK2.
  • activated MEKs catalyse phosphorylation and activation of p42/p44 mitogen-activated protein kinase (MAPK).
  • a variety of cytoplasmic and nuclear substrates of activated MAPK are known which directly or indirectly contribute to the cellular response to environmental change.
  • Three distinct genes have been identified in mammals that encode Raf proteins; A-Raf, B-Raf and C-Raf (also known as Raf-1) and isoformic variants that result from differential splicing of mRNA are known.
  • Inhibitors of Raf kinases have been suggested for use in disruption of tumor cell growth and hence in the treatment of cancers, e.g. histiocytic lymphoma, lung adenocarcinoma, small cell lung cancer and pancreatic and breast carcinoma.
  • Raf inhibitors are useful in the treatment and/or prophylaxis of disorders associated with neuronal degeneration resulting from ischemic events, including cerebral ischemia after cardiac arrest, stroke and multi-infarct dementia and also after cerebral ischemic events such as those resulting from surgery and/or during childbirth.
  • a method of treatment or prophylaxis of a neurotraumatic disease in a mammal in need thereof, which comprises administering to said mammal an effective amount of a Raf inhibitor.
  • Raf inhibitor in the manufacture of a medicament for the prophylactic or therapeutic treatment of a disease state in a human, or other mammal, which is exacerbated or caused by a neurotraumatic event.
  • the Raf inhibitor for use in the invention is preferably a B-Raf inhibitor.
  • Neurotraumatic diseases/events as defined herein include both open or penetrating head trauma, such as caused by surgery, or a closed head trauma injury, such as caused by an injury to the head region.
  • ischemic stroke particularly to the brain area, transient ischemic attacks following coronary by-pass and cognitive decline following other transient ischemic conditions.
  • Ischemic stroke may be defined as a focal neurologic disorder that results from insufficient blood supply to a particular brain area, usually as a consequence of an embolus, thrombi, or local atheromatous closure of the blood vessel.
  • the definition Raf inhibitor is also intended to encompass antisense constructs that result in a reduced expression of a Raf kinase within a target cell.
  • Small molecule Raf inhibitors include those described in GB2306108,
  • Raf inhibitor 4-(4-chloro-3- hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole.
  • the use of this compound for the treatment of Raf-mediated cancers is described in Poster 3793, American Association of Cancer Research, New Jersey, April 1998.
  • Antisense Raf inhibitors include those described in WO97/10829, US5656612, WO99/02167, US5872232 and WO96/39415.
  • Raf inhibitors In order to use Raf inhibitors in therapy, they will normally be formulated into a pharmaceutical composition in accordance with standard pharmaceutical practice.
  • Inhibitors may conveniently be administered by any of the routes conventionally used for drug administration, for instance, parenterally, orally, topically or by inhalation. Inhibitors may be administered in conventional dosage forms prepared by combining it with standard pharmaceutical carriers according to conventional procedures. Inhibitors may also be administered in conventional dosages in combination with a known, second therapeutically active compound. These procedures may involve mixing, granulating and compressing or dissolving the ingredients as appropriate to the desired preparation. It will be appreciated that the form and character of the pharmaceutically acceptable carrier is dictated by the amount of active ingredient with which it is to be combined, the route of administration and other well-known variables. The carrier(s) must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.
  • the pharmaceutical carrier employed may be, for example, either a solid or liquid.
  • solid carriers are lactose, terra alba, sucrose, talc, gelatin, agar, pectin, acacia, magnesium stearate, stearic acid and the like.
  • liquid carriers are syrup, peanut oil, olive oil, water and the like.
  • the carrier or diluent may include time delay material well known to the art, such as glyceryl mono- stearate or glyceryl distearate alone or with a wax.
  • time delay material well known to the art, such as glyceryl mono- stearate or glyceryl distearate alone or with a wax.
  • a wide variety of pharmaceutical forms can be employed.
  • the preparation can be tableted, placed in a hard gelatin capsule in powder or pellet form or in the form of a troche or lozenge. The amount of solid carrier will van'
  • the preparation will be in the form of a syrup, emulsion, soft gelatin capsule, sterile injectable liquid such as an ampoule or nonaqueous liquid suspension.
  • Inhibitors are preferably administered parenterally, that is by intravenous, intramuscular, subcutaneous intranasal, intrarectal, intravaginal or intraperitoneal administration.
  • the intravenous form of parenteral administration is generally preferred.
  • Appropriate dosage forms for such administration may be prepared by conventional techniques.
  • Inhibitors may also be administered orally.
  • Appropriate dosage forms for such administration may be prepared by conventional techniques.
  • Inhibitors may also be administered by inhalation, that is by intranasal and oral inhalation administration.
  • Appropriate dosage forms for such administration such as aerosol formulations, may be prepared by conventional techniques.
  • Inhibitors may also be administered topically, that is by non-systemic administration. This includes the application of the inhibitors externally to the epidermis or the buccal cavity and the instillation of such a compound into the ear, eye and nose, such that the compound does not significantly enter the blood stream.
  • the daily oral dosage regimen will preferably be from about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to 30 mg kg, more preferably from about 0.5 mg to 15mg.
  • the daily parenteral dosage regimen about 0.1 to about 80 mg/kg of total body weight, preferably from about 0.2 to about 30 mg/kg, and more preferably from about 0.5 mg to 15mg/kg.
  • the daily topical dosage regimen will preferably be from 0.1 mg to 150 mg, administered one to four, preferably two or three times daily.
  • the daily inhalation dosage regimen will preferably be from about 0.01 mg kg to about 1 mg kg per day.
  • the optimal quantity and spacing of individual dosages of the inhibitors will be determined by the nature and extent of the condition being treated, the form, route and site of administration, and the particular patient being treated, and that such optimums can be determined by conventional techniques. It will also be appreciated by one of skill in the art that the optimal course of treatment, i.e., the number of doses of the inhibitors given per day for a defined number of days, can be ascertained by those skilled in the art using conventional course of treatment determination tests.
  • the sub-title compound was prepared from 4-chloro-3-methoxybenzoic acid, via its acid chloride, by analogy to the five step procedure (general method B) described by T. F. Gallagher et al, Bioorg. Med. Chem., (1997), 5, 49: MS m/z 362/364 M ⁇ + (electrospray).
  • step b) 4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(4-pyridyl)-lH-imidazole Boron tribromide (5.6 ml, 1M in dichloromethane, 5.6mmol) was added to an ice-cooled solution of the product of step a) (670 mg, 1.85 mmol) in dichloromethane (20 ml). The solution was allowed to warm to ambient temperature and stirred for a further 16h. 5M hydrochloric acid (5 ml) was then added and the mixture heated to reflux for 30 min. After cooling the solution was made alkaline with 40% aqueous sodium hydroxide and the solid product collected by filtration. The residue was washed with ethyl acetate to afford the title compound as a yellow solid: MS m/z 348/350 M ⁇ + (electrospray).
  • the activity of compounds as Raf inhibitors may be determined by the following in vitro assay: Raf Kinase assay
  • MAP kinase MAP kinase
  • Catalytically active human recombinant B-Raf protein was obtained by purification from sf9 insect cells infected with a human B-Raf recombinant baculovirus expression vector. To ensure that all substrate phosphorylation resulted from B-Raf activity, a catalytically inactive form of MEK was utilised.
  • This protein was purified from bacterial cells expression mutant inactive MEK as a fusion protein with glutathione-S-transferase (GST- kdMEK).
  • GST- kdMEK glutathione-S-transferase
  • the neuroprotective properties of Raf inhibitors may be determined by the following in vitro assay: Neuroprotective properties of 4-(4-Chloro-3-hydroxyphenyl)-2-phenyl-5-(4- pyridyl)-lH-imidazole in rat hippocampal slice cultures
  • Organotypic cultures provide an intermediate between dissociated neuronal cell cultures and in-vivo models of oxygen and glucose deprivation (OGD).
  • OGD oxygen and glucose deprivation
  • the majority of glial-neuronal interactions and neuronal circuitry are maintained in cultured hippocampal slices, so facilitating investigation of the patterns of death among differing cell types in a model that resembles the in vivo situation.
  • These cultures allow the study of delayed cellular damage and death 24 hours, or more, post-insult and permit assessment of the consequences of long-term alterations in culture conditions.
  • Bound PI shows increased emission at 635nm when excited at 540nm.
  • One PI fluorescence image and one white light image are taken and the proportion of cell death analysed.
  • the area of region CA1 is defined from the white light image and superimposed over the PI image.
  • the PI signal is thresholded and area of PI damage expressed as a percentage of the CA1 area. Correlation between PI fluorescence and histo logically confirmed cell death has been validated previously by Nissl-staining using cresyl fast violet (Newell et al, J Neurosci., (1995b) 15: 7702-7711).
  • B-Raf inhibitors are effective inhibitor of the catalytic activity of human B-Raf protein kinase towards its physiologic substrate MAP kinase (MEK). Moreover, B-Raf inhibitors are potent inhibitors of neuronal cell death that results from oxygen glucose deprivation in hippocampal slice cultures. Such neuroprotective properties indicate that B-Raf inhibitors are likely to be of value in prevention of neuronal cell death associated with ischemic stroke and trauma injury.
  • MEK MAP kinase

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne l'utilisation d'inhibiteurs de kinases Raf dans le traitement de maladies neurotraumatiques.
EP00927054A 1999-04-27 2000-04-26 Nouveau traitement de conditions neurotraumatiques avec un inhibiteur de raf Withdrawn EP1173254A2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB9909650 1999-04-27
GBGB9909650.5A GB9909650D0 (en) 1999-04-27 1999-04-27 Novel treatment
GB9916655 1999-07-15
GBGB9916655.5A GB9916655D0 (en) 1999-07-15 1999-07-15 Novel treatment
PCT/EP2000/003730 WO2000064422A2 (fr) 1999-04-27 2000-04-26 Nouveau traitement

Publications (1)

Publication Number Publication Date
EP1173254A2 true EP1173254A2 (fr) 2002-01-23

Family

ID=26315478

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00927054A Withdrawn EP1173254A2 (fr) 1999-04-27 2000-04-26 Nouveau traitement de conditions neurotraumatiques avec un inhibiteur de raf

Country Status (4)

Country Link
EP (1) EP1173254A2 (fr)
JP (1) JP2002542280A (fr)
AU (1) AU4556800A (fr)
WO (1) WO2000064422A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1529901A (en) 1999-11-22 2001-06-04 Smithkline Beecham Plc Compounds
GB0112348D0 (en) 2001-05-19 2001-07-11 Smithkline Beecham Plc Compounds
WO2003022832A1 (fr) * 2001-09-05 2003-03-20 Smithkline Beecham P.L.C. Pyridylfurans et pyrroles inhibiteurs de la kinase raf
GB0121488D0 (en) * 2001-09-05 2001-10-24 Smithkline Beecham Plc Compounds
WO2004019873A2 (fr) 2002-08-29 2004-03-11 Scios Inc. Methode pour favoriser l'osteogenese
WO2005030091A2 (fr) 2003-09-25 2005-04-07 Scios Inc. Stents et protheses intra-luminales contenant des inhibiteurs de kinase map
MXPA06014696A (es) * 2004-06-15 2007-02-12 Astrazeneca Ab Quinazolonas sustituidas como agentes anticancerosos.
EP1676574A3 (fr) 2004-12-30 2006-07-26 Johnson & Johnson Vision Care, Inc. Procédé favorisant la survie des tissus ou cellules griffées
TW200639163A (en) 2005-02-04 2006-11-16 Genentech Inc RAF inhibitor compounds and methods
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991017156A1 (fr) * 1990-05-10 1991-11-14 Pfizer Inc Indolone neuroprotecteur et derives apparentes
US5498610A (en) * 1992-11-06 1996-03-12 Pfizer Inc. Neuroprotective indolone and related derivatives
WO1994015645A1 (fr) * 1992-12-31 1994-07-21 Texas Biotechnology Corporation MOLECULES ANTISENS DIRIGEES CONTRE LES GENES DE LA FAMILLE DES ONCOGENES $i(RAF)
GB2306108A (en) * 1995-10-13 1997-04-30 Merck & Co Inc Treatment of Raf-mediated cancers with imidazole derivatives
EP0889887A4 (fr) * 1996-03-25 2003-06-11 Smithkline Beecham Corp Nouveau traitement de lesions du systeme nerveux central
CA2272578A1 (fr) * 1996-11-18 1998-05-28 Mcgill University Neurones post-mitotiques contenant des vecteurs a base d'adenovirus qui modulent l'apoptose et la croissance
GB9716557D0 (en) * 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6022884A (en) * 1997-11-07 2000-02-08 Amgen Inc. Substituted pyridine compounds and methods of use

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
None *
See also references of WO0064422A3 *

Also Published As

Publication number Publication date
JP2002542280A (ja) 2002-12-10
WO2000064422A2 (fr) 2000-11-02
AU4556800A (en) 2000-11-10
WO2000064422A3 (fr) 2001-03-01

Similar Documents

Publication Publication Date Title
Jane et al. Coadministration of sorafenib with rottlerin potently inhibits cell proliferation and migration in human malignant glioma cells
EP1318992B1 (fr) Derives d'imidazole en tant qu'inhibiteurs de la raf kinase
JP7671327B2 (ja) 消化管間質腫瘍の治療のための併用療法
EP1263753B1 (fr) Derives imidazole utilises comme inhibiteurs de la raf kinase
EP1397354B1 (fr) Derives d'imidazole-2-carboxamide utilises comme inhibiteurs de raf kinase
US20120238597A1 (en) Inhibiting EPH B-3 Kinase
EP1755611A1 (fr) Inhibition de la phosphodiesterase 10 dans le traitement des etats pathologiques associes a l'obesite et au syndrome metabolique
JP2023521753A (ja) 抗ウイルス療法
EP1423383B1 (fr) Derives furaniques substitues par une pyridine servant d'inhibiteurs de raf kinase
CA2534432A1 (fr) Procedes pour traiter le diabete, et les troubles associes, au moyen d'inhibiteurs des pde10a
CZ93097A3 (en) 5-ht1f mediated inhibition of neurogenic meningeal extravasate
CN111053768A (zh) 用于治疗黑素瘤的药物组合
JPH04226917A (ja) 神経退化過程における予防及び治療用医薬
EP1173254A2 (fr) Nouveau traitement de conditions neurotraumatiques avec un inhibiteur de raf
EP1313478A2 (fr) Traitement de la migraine par des inhibiteurs de pde5
EP1432697A1 (fr) Pyridylfurans et pyrroles inhibiteurs de la kinase raf
Li et al. Discovering single cannabidiol or synergistic antitumor effects of cannabidiol and cytokine-induced killer cells on non-small cell lung cancer cells
US20080045500A1 (en) Nerve Regeneration Stimulator
US20040192689A1 (en) Heterocycle-carboxamide derivatives as raf kinase inhibitors
EP1432702B1 (fr) Composes heterocycliques azotes, et leur utilisation comme inhibiteurs de proteine raf
EP4433054A1 (fr) Nitroxoline destinée à être utilisée dans le traitement ou la prévention d'un neurofibrome plexiforme
US20040198730A1 (en) Pyridylfurans and pyrroles as raf kinase inhibitors
US20240366601A1 (en) Methods for treating traumatic brain injury
HK40026870A (en) A pharmaceutical combination for the treatment of melanoma
Elkhrbash The role of angiotensin AT1 and AT2 receptors in the development of apoptosis and inflammation following experimental myocardial infarction

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011015

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SMITHKLINE BEECHAM PLC

17Q First examination report despatched

Effective date: 20031127

RTI1 Title (correction)

Free format text: TREATMENT OF NEUROTRAUMATIC CONDITIONS WITH A RAF INHIBITOR

17Q First examination report despatched

Effective date: 20031127

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070524